FIELD: pharmaceuticals.
SUBSTANCE: present invention refers to a pharmaceutical composition for treating cystic fibrosis in children younger than 6 years old. Composition contains a solid dispersion containing N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, hydroxypropyl methyl cellulose acetate succinate, sodium lauryl sulphate, mannitol and lactose, sucralose, sodium croscarmellose, colloidal silicon dioxide and magnesium stearate. Mannitol and lactose are presented in weight ratio of 1:3, respectively. Composition does not contain sodium lauryl sulphate anywhere other than the solid dispersion. Composition is presented in the form of a single dosage form containing one or more granules or mini-tablets. Also described is a method of treating or reducing the severity of cystic fibrosis in a child of less than 6 years old using said pharmaceutical composition.
EFFECT: granular composition of the invention is characterized by a satisfactory bioavailability profile and physical stability.
23 cl, 2 dwg, 22 tbl, 22 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION AND ITS ADMINISTERING | 2013 |
|
RU2802442C2 |
SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUBSTITUTED INDANE, AND METHODS FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2772693C1 |
COMPOSITIONS OF SOLID DOSAGE FORMS OF OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2759837C2 |
METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS FOR TREATING CFTR MEDIATED DISEASES | 2014 |
|
RU2718044C2 |
COMPOSITIONS OF SOLID DOSAGE FORMS OF AN OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2699358C2 |
PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES MEDIATED BY A TRANSMEMBRANE REGULATOR OF CYSTIC FIBROSIS (CFTR) | 2013 |
|
RU2692676C2 |
PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBRIOSIS | 2019 |
|
RU2822220C2 |
SOLID DISPERSIONS | 2016 |
|
RU2694832C2 |
TABLETS PREPARATION TECHNOLOGY FOR CGRP-ACTIVE COMPOUNDS | 2015 |
|
RU2696578C1 |
PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE | 2016 |
|
RU2736941C2 |
Authors
Dates
2019-06-27—Published
2013-02-27—Filed